A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways
Abstract Background As a member of the Janus kinase (JAK) family, which includes JAK1, JAK2 and JAK3, tyrosine kinase 2 (TYK2) plays an important role in signal transduction and immune system regulation. Moreover, it is also involved in the development of many types of inflammatory and autoimmune di...
Main Authors: | Celia X.-J. Chen, Wei Zhang, Shulan Qu, Fucan Xia, Yidong Zhu, Bo Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | Cell Communication and Signaling |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12964-023-01299-7 |
Similar Items
-
Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases
by: Zhiqin Fang, et al.
Published: (2023-11-01) -
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
by: Lise Torp Jensen, et al.
Published: (2023-11-01) -
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr.
Published: (2023-03-01) -
JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling
by: Alice H. Grant, et al.
Published: (2023-04-01) -
Mesenchymal stem cells alleviate psoriasis-like dermatitis in mice by inhibiting TYK2 phosphorylation
by: Lina LIANG, et al.
Published: (2022-06-01)